|
When added to MRI, gadolinium-based contrast agents were found to substantially enhance the malignancy criteria for primary tumor visualization, as well as increase the accuracy in the detection of lymph node metastases, according to a meta-analysis published in the February edition of the Journal of the National Cancer Institute.
After years of research regarding gadolinium-based contrast agents used during MRI being linked to the skin disease nephrogenic systemic fibrosis (NSF), the FDA has found the greatest risk in GE Healthcare’s Omniscan, Bayer HealthCare's Magnevist and Covidien’s Optimark.
|
Acute adverse reactions from gadolinium-based contrast agents used during MRI to help improve the information seen on the images rarely occur, according to a study published in the February issue of the American Journal of Roentgenology.
|
RSS 
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
During the Health IT Standards Committee meeting on Feb. 24 in Washington, D.C., the Clinical Operations Workgroup sought to gather comments on proposed recommendations on implementation specifications for content exchange, vocabulary and code set standards for the Interim Final Rule of meaningful use.
In 2006, the Center for Devices and Radiological Health (CDRH), a branch of the FDA, began examining the number of medical device reports they received. Over the past two years, the number of submitted reports has increased, sparking a demand for the CDRH to make a move to electronic reporting.
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.